Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors

Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5’-nucleotidase (CD...

Full description

Bibliographic Details
Main Authors: Laura Schäkel, Constanze C. Schmies, Riham M. Idris, Xihuan Luo, Sang-Yong Lee, Vittoria Lopez, Salahuddin Mirza, The Hung Vu, Julie Pelletier, Jean Sévigny, Vigneshwaran Namasivayam, Christa E. Müller
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
ARL67156
CD39
CD73
docking
dual-target inhibitors
ecto-5’-nucleotidase
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01294/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01294/full

Similar Items